From 1999 through 2020, Black Americans experienced more than 1.6 million excess deaths and more than 80 million excess years of life lost compared to white Americans, according to a recent study published in JAMA.
A team led by Northwestern Medicine investigators have discovered novel cellular mechanisms that lead to chemotherapy resistance in recurrent glioblastoma, according to findings published in Science Advances.
An informational communications tool provided to patients with dilated cardiomyopathy helped increase cardiovascular screenings in their first-degree relatives who have a higher risk of developing the genetic disease, according to findings published in Circulation.
Investigators led by Barbara Stranger, PhD, associate professor of Pharmacology, developed a guide outlining best practices for studying and testing sex-dependent genetic effects in complex traits and diseases, published in the journal Cell.
Northwestern University Feinberg School of Medicine has again been recognized as one of the best medical schools in the nation, ranking 13th among research-oriented institutions, according to the latest U.S. News & World Report rankings.
Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery, according to a recent study published in Nature Medicine.
A novel protein developed by Northwestern Medicine investigators improved survival and prevented brain infection in mice infected with SARS-CoV-2 when administered intranasally, according to a recent study.
Ann & Robert H. Lurie Children’s Hospital of Chicago is the first in Illinois to receive designation as a NORD Rare Disease Center of Excellence, becoming one of 40 U.S. academic medical centers selected to be a part of the first-of-it-kind national network of U.S. medical institutions dedicated to diagnosing, treating, and researching all rare…
Richard Silverman, PhD, along with two other Northwestern faculty members, has been elected to the National Academy of Sciences.
Patients with endometrial cancer who received the immunotherapy drug pembrolizumab in addition to chemotherapy had longer progression-free survival compared to chemotherapy alone, according to a recent clinical trial published in the New England Journal of Medicine.